- Report
- February 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- August 2024
- 164 Pages
Global
From €4734EUR$4,995USD£3,955GBP
- Report
- February 2021
- 420 Pages
United States
From €2047EUR$2,160USD£1,710GBP
€2275EUR$2,400USD£1,900GBP
- Report
- August 2022
- 117 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- February 2023
- 198 Pages
Global
From €7109EUR$7,500USD£5,939GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Book
- February 2024
- 592 Pages
Doxepin is a tricyclic antidepressant used to treat depression, anxiety, and insomnia. It is classified as a central nervous system (CNS) drug, and is one of the most commonly prescribed antidepressants in the United States. Doxepin works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters that are involved in regulating mood. It is available in both oral and topical forms, and is often used in combination with other medications to treat depression.
Doxepin is generally well-tolerated, but can cause side effects such as dry mouth, drowsiness, and blurred vision. It is important to discuss any potential risks with a healthcare provider before taking doxepin.
The doxepin market is highly competitive, with many pharmaceutical companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more